東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Leveraging TCR Signaling for the Des...

Bugos, Grace,

Linked to FindBook

Google Book

Amazon

博客來

Leveraging TCR Signaling for the Design of Sensitive Bispecific Receptors for Cancer Therapy /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Leveraging TCR Signaling for the Design of Sensitive Bispecific Receptors for Cancer Therapy // Grace Bugos.
Author:	Bugos, Grace,
Description:	1 electronic resource (111 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 86-07, Section: B.
Contained By:	Dissertations Abstracts International86-07B.
Subject:	Immunology. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31764540
ISBN:	9798302155498

Leveraging TCR Signaling for the Design of Sensitive Bispecific Receptors for Cancer Therapy /
Bugos, Grace,

Leveraging TCR Signaling for the Design of Sensitive Bispecific Receptors for Cancer Therapy /Grace Bugos. - 1 electronic resource (111 pages)

Source: Dissertations Abstracts International, Volume: 86-07, Section: B.

Immune-based therapies have revolutionized the treatment of cancer by improving the immune system's capacity to target and kill cancer cells. These advances were built on foundational research in immunology, underscoring that continued immunology research is critical to the improvement of human health. Adoptive T cell therapies, particularly chimeric antigen receptors (CAR) T cell therapies exemplify the direct impact of fundamental immunology on treatment innovations. Chimeric Antigen Receptors (CARs) are engineered by combining and extracellular binding domain with signaling molecules essential T cell activation into one molecule, enabling specific activation of T cells to target tumor cells expressing the ligand for the extracellular binder. Research in T cell biology, particularly the T cell receptor (TCR) enabled the design of CARs by identifying essential TCR activation signals that were incorporated in the CAR architecture. Thousands of patients have been treated with CAR T cell therapies, with remarkable success, particularly in therapy of B cell malignancies and multiple myeloma. However, further advances are required to overcome the escape of tumor cells that express low levels or lack the target antigen improve the durability of responses and expand the application T cell therapies. This thesis presents the development a novel class of receptors for adoptive T cell therapy, termed chimeric T cell receptors (ChTCRs)that provide improved sensitivity and specificity over traditional CAR T cell therapies. Our receptor design leverages an understanding of TCR signaling to more closely mimic native TCR signaling, and improves receptor sensitivity. This approach led to the development of two novel receptors: the monospecific 'Full ChTCR,' which has superior antigen sensitivity and tumor control in pre-clinical mouse models relative to existing CARs and other ChTCR variants, and the dual-antigen targeting 'Bi-ChTCR,' which has enhanced sensitivity and ePicacy in to targeting heterogenous tumors compared to monospecific and bispecific CARs.Additionally, I developed a mass cytometry tool to determine similarities and diPerences in proximal receptor signaling in engineered T cells and understand how improved signaling may impact cell diPerentiation and function. Collectively this work demonstrates the value of TCR signaling research in guiding novel receptor design for adoptive T cell therapies. It introduces a tool to study signaling dynamics and reports an adaptable receptor architecture for sensitive targeting of tumor antigen.

English

ISBN: 9798302155498Subjects--Topical Terms:

611031
Immunology.
Subjects--Index Terms:

Immune-based therapies

Leveraging TCR Signaling for the Design of Sensitive Bispecific Receptors for Cancer Therapy /
LDR:04036nmm a22004333i 4500 001 2436533
005 20251023121237.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798302155498
035 $a (MiAaPQD)AAI31764540
035 $a AAI31764540
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Bugos, Grace, $e author. $3 3827223
245 1 0 $a Leveraging TCR Signaling for the Design of Sensitive Bispecific Receptors for Cancer Therapy / $c Grace Bugos.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (111 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-07, Section: B.
500 $a Advisors: Riddell, Stanley Committee members: Newell, Evan; Dudakov, Jarrod.
502 $b Ph.D. $c University of Washington $d 2024.
520 $a Immune-based therapies have revolutionized the treatment of cancer by improving the immune system's capacity to target and kill cancer cells. These advances were built on foundational research in immunology, underscoring that continued immunology research is critical to the improvement of human health. Adoptive T cell therapies, particularly chimeric antigen receptors (CAR) T cell therapies exemplify the direct impact of fundamental immunology on treatment innovations. Chimeric Antigen Receptors (CARs) are engineered by combining and extracellular binding domain with signaling molecules essential T cell activation into one molecule, enabling specific activation of T cells to target tumor cells expressing the ligand for the extracellular binder. Research in T cell biology, particularly the T cell receptor (TCR) enabled the design of CARs by identifying essential TCR activation signals that were incorporated in the CAR architecture. Thousands of patients have been treated with CAR T cell therapies, with remarkable success, particularly in therapy of B cell malignancies and multiple myeloma. However, further advances are required to overcome the escape of tumor cells that express low levels or lack the target antigen improve the durability of responses and expand the application T cell therapies. This thesis presents the development a novel class of receptors for adoptive T cell therapy, termed chimeric T cell receptors (ChTCRs)that provide improved sensitivity and specificity over traditional CAR T cell therapies. Our receptor design leverages an understanding of TCR signaling to more closely mimic native TCR signaling, and improves receptor sensitivity. This approach led to the development of two novel receptors: the monospecific 'Full ChTCR,' which has superior antigen sensitivity and tumor control in pre-clinical mouse models relative to existing CARs and other ChTCR variants, and the dual-antigen targeting 'Bi-ChTCR,' which has enhanced sensitivity and ePicacy in to targeting heterogenous tumors compared to monospecific and bispecific CARs.Additionally, I developed a mass cytometry tool to determine similarities and diPerences in proximal receptor signaling in engineered T cells and understand how improved signaling may impact cell diPerentiation and function. Collectively this work demonstrates the value of TCR signaling research in guiding novel receptor design for adoptive T cell therapies. It introduces a tool to study signaling dynamics and reports an adaptable receptor architecture for sensitive targeting of tumor antigen.
546 $a English
590 $a School code: 0250
650 4 $a Immunology. $3 611031
650 4 $a Cellular biology. $3 3172791
650 4 $a Oncology. $3 751006
653 $a Immune-based therapies
653 $a Chimeric Antigen Receptors
653 $a T cell receptor
653 $a Extracellular binder
653 $a Tumor antigen
690 $a 0982
690 $a 0379
690 $a 0992
710 2 $a University of Washington. $b Immunology. $e degree granting institution. $3 3827224
720 1 $a Riddell, Stanley $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-07B.
790 $a 0250
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31764540